biliary tract cancer
Oncology · 2023–2024
3decisions
2medicines
3carried consumer input
16individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ivosidenib Treatment of locally advanced or metastatic cholangiocarcinoma in patients with an IDH1 R132 variant whose disease has progressed on at least one prior line of… | Nov 2024 | Recommended | 12 individuals |
| durvalumab First-line treatment of patients with locally advanced, metastatic, or recurrent biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic… | Jul 2023 | Recommended with restriction | input received Medical Oncology Group |
| durvalumab First-line treatment of patients with advanced biliary tract cancer (locally advanced unresectable, metastatic, or recurrent disease) in combination with… | Mar 2023 | Recommended with restriction | 4 individuals Cholangiocarcinoma Foundation Australia · Rare Cancers Australia · Australasian Gastro Intestinal Trials Group · PanCare Foundation · Medical Oncology Group |
Who spoke
Medical Oncology Group · Cholangiocarcinoma Foundation Australia · Rare Cancers Australia · Australasian Gastro Intestinal Trials Group · PanCare Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.